Biocompatible blood pool MRI contrast agents based on hyaluronan

Contrast Media and Molecular Imaging

Volumn 6, Issue 2, 2011, Pages 61-68

  Zhu, Wenlian ^a   Artemov, Dmitri ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biocompatible contrast agents; Hyaluronan; Magnetic resonance angiography

Indexed keywords

ETHYLENEDIAMINE; GADOLINIUM; GLUCURONIC ACID; HYALURONIC ACID; N ACETYLGLUCOSAMINE; PENTETIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; EXTRACELLULAR MATRIX; GASTROINTESTINAL TRACT; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; STOMACH;

ANIMALS; CONTRAST MEDIA; ETHYLENEDIAMINES; GADOLINIUM; HYALURONIC ACID; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; PENTETIC ACID;

EID: 79955032395     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.404     Document Type: Article

References (34)

1. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3(3): 319-328.
2. Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008; 4(1): 1-9.
3. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 2001; 14(3): 237-242.
4. Baxter AB, Melnikoff S, Stites DP, Brasch RC. AUR Memorial Award 1991.Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging. Induction and characterization of antibodies in animals. Invest Radiol 1991; 26(12): 1035-1040.
5. Bogdanov AA Jr, Weissleder R, Frank HW, Bogdanova AV, Nossif N, Schaffer BK, Tsai E, Papisov MI, Brady TJ. A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 1993; 187(3): 701-706.
6. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008; 43(12): 817-828.
7. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18(10): 2164-2173.
8. Franano FN, Edwards WB, Welch MJ, Brechbiel MW, Gansow OA, Duncan JR. Biodistribution and metabolism of targeted and nontargeted protein-chelate-gadolinium complexes: evidence for gadolinium dissociation in vitro and in vivo. Magn Reson Imaging 1995; 13(2): 201-214.
9. Takakura Y, Mahato RI, Hashida M. Extravasation of macromolecules. Adv Drug Deliv Rev 1998; 34(1): 93-108.
10. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55(3): 425-461.
11. Chong BF, Blank LM, McLaughlin R, Nielsen LK. Microbial hyaluronic acid production. Appl Microbiol Biotechnol 2005; 66(4): 341-351.
12. Guillaumie F, Furrer P, Felt-Baeyens O, Fuhlendorff BL, Nymand S, Westh P, Gurny R, Schwach-Abdellaoui K. Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications. J Biomed Mater Res A 2009.
13. Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 2007; 29(1): 17-25.
14. Brown TJ. The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs. Curr Pharm Biotechnol 2008; 9(4): 253-260.
15. Esposito G, Geninatti Crich S, Aime S. Efficient cellular labeling by CD44 receptor-mediated uptake of cationic liposomes functionalized with hyaluronic acid and loaded with MRI contrast agents. ChemMedChem 2008; 3(12): 1858-1862.
16. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008; 5(4): 474-486.
17. Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks LE, Brito AC, Brasch RC. Albumin labeled with Gd-DTPA as an intravascular, blood pool-enhancing agent for MR imaging: biodistribution and imaging studies. Radiology 1987; 162(1 Pt 1): 205-210.
18. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1987; 22(8): 665-671.
19. Shiftan L, Israely T, Cohen M, Frydman V, Dafni H, Stern R, Neeman M. Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. Cancer Res 2005; 65(22): 10316-10323.
20. Gouin S, Winnik FM. Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry. Bioconjug Chem 2001; 12(3): 372-377.
21. Haynes WM. CRC Handbook of Chemistry and Physics. 91st edn. Boca Raton, FL: CRC Press; 2010-2011. p 8-42.
22. Kuo JW, Swann DA, Prestwich GD. Chemical modification of hyaluronic acid by carbodiimides. Bioconjug Chem 1991; 2(4): 232-241.
23. Cowman MK, Matsuoka S. Experimental approaches to hyaluronan structure. Carbohydr Res 2005; 340(5): 791-809.
24. Blundell CD, Deangelis PL, Almond A. Hyaluronan: the absence of amide-carboxylate hydrogen bonds and the chain conformation in aqueous solution are incompatible with stable secondary and tertiary structure models. Biochem J 2006; 396(3): 487-498.
25. Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 2006; 106(3): 818-839.
26. Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007; 282(8): 5597-5607.
27. Jackson DG. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 2009; 230(1): 216-231.
28. Lebel L. Clearance of hyaluronan from the circulation. Adv Drug Deliv Rev 1991; 7(2): 221-235.
29. Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imag 2009; 4(1): 1-23.
30. Sherry AD, Cacheris WP, Kuan KT. Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: implications for their use as magnetic resonance contrast agents. Magn Reson Med 1988; 8(2): 180-190.
31. Lebel L, Fraser JR, Kimpton WS, Gabrielsson J, Gerdin B, Laurent TC. A pharmacokinetic model of intravenously administered hyaluronan in sheep. Pharm Res 1989; 6(8): 677-682.
32. Fraser JR, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981; 200(2): 415-424.
33. Nakabayashi H, Tsujii H, Okamoto Y, Nakano H. Fluorescence-labeled-hyaluronan loading test as an index of hepatic sinusoidal endothelial cell function in the rat. Int Hepatol Commun 1996; 5(6): 345-353.
34. Mochizuki S, Kano A, Shimada N, Maruyama A. Uptake of enzymatically-digested hyaluronan by liver endothelial cells in vivo and in vitro. J Biomater Sci Polym Ed 2009; 20(1): 83-97.